Zylox Tonbridge (2190 HK): Domestic Holds, International Stellar in 1H26, Pipeline and Launches Key
Zylox TB posted 31% YoY higher sales due to growth witnessed across segments. International business was robust. Global growth prospects will...
93 Views
Zylox Tonbridge (2190 HK): 2025 Good; International Presence, Product Launches Will Shape the Future
Zylox-Tonbridge Medical Technology (2190 HK) sees strong revenue growth driven by neurovascular and peripheral vascular devices. International...
223 Views
Zylox Tonbridge (2190 HK): Optimed Acquisition Is a Positive Step Forward Towards Future Growth
Zylox-Tonbridge Medical Technology (2190 HK) acquires 49% stake in Optimed GmbH for EUR 18.4M, boosting international expansion with product...
285 Views
Zylox Tonbridge Medical (2190 HK): No More Interventions Needed, Blockages Cleared for Growth
Zylox-Tonbridge Medical carried forward 2024 momentum, moving into 1H25. New launches and strong market sales capabilities will help drive the...
438 Views
Zylox-Tonbridge Medical Technology (2190.HK) - A Good Alpha-Generating Opportunity for Investors
Zylox's strong fundamentals and growth potential have not been fully reflected in current valuation due to market conditions, making it a...
596 Views